ReviewNPJ schizophrenia2020
The role of nicotinic cholinergic neurotransmission in delusional thinking.
Review in NPJ schizophrenia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials.BMC psychiatry · 2025Pooled it
- Clinical and Structural Differences in Delusions Across Diagnoses: A Systematic Review.Frontiers in integrative neuroscience · 2021Pooled it
- Moderating Role of Cigarette Smoking on the Efficacy of tDCS in the Treatment of Negative and Cognitive Symptoms of Schizophrenia: Results from a Randomized Clinical Trial.Brain sciences · 2026Article
- A comprehensive review on schizophrenia: epidemiology, pathogenesis, diagnosis, conventional treatments, and proposed natural compounds used for management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Epigenetic Control in Schizophrenia.Sub-cellular biochemistry · 2025Review
- Cross-ancestry genetic investigation of schizophrenia, cannabis use disorder, and tobacco smoking.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Genetic Implication of Prenatal GABAergic and Cholinergic Neuron Development in Susceptibility to Schizophrenia.Schizophrenia bulletin · 2024Article
- Detecting outliers in case-control cohorts for improving deep learning networks on Schizophrenia prediction.Journal of integrative bioinformatics · 2024Article
- The New Horizon of Antipsychotics beyond the Classic Dopaminergic Hypothesis-The Case of the Xanomeline-Trospium Combination: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Generation of Functional and Mature Sympathetic Neurons from Human Pluripotent Stem Cells via a Neuroepithelial Route.Journal of molecular neuroscience : MN · 2024Article
- Cross-ancestry genetic investigation of schizophrenia, cannabis use disorder, and tobacco smoking.medRxiv : the preprint server for health sciences · 2024Article
- Genetic implication of prenatal GABAergic and cholinergic neuron development in susceptibility to schizophrenia.medRxiv : the preprint server for health sciences · 2023Article
- Unprecedented effect of vitamin D3 on T-cell receptor beta subunit and alpha7 nicotinic acetylcholine receptor expression in a 3-nitropropionic acid induced mouse model of Huntington's disease.IBRO neuroscience reports · 2023Article
- Basal-Forebrain Cholinergic Nuclei Alterations are Associated With Medication and Cognitive Deficits Across the Schizophrenia Spectrum.Schizophrenia bulletin · 2023Article
- Review
- Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia.CNS drugs · 2023Review
- Cholinergic Antagonists and Behavioral Disturbances in Neurodegenerative Diseases.International journal of molecular sciences · 2023Review
- Cholinergic receptor-Wnt pathway controls immune activation by sensing intestinal dysfunction.Cell reports · 2022Article
- Microstructural imaging and transcriptomics of the basal forebrain in first-episode psychosis.Translational psychiatry · 2022Article
- Incorporating regulatory interactions into gene-set analyses for GWAS data: A controlled analysis with the MAGMA tool.PLoS computational biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delusions are a difficult-to-treat and intellectually fascinating aspect of many psychiatric illnesses. Although scientific progress on this complex topic has been challenging, some recent advances focus on dysfunction in neural circuits, specifically in those involving dopaminergic and glutamatergic neurotransmission. Here we review the role of cholinergic neurotransmission in delusions, with a focus on nicotinic receptors, which are known to play a part in some illnesses where these symptoms appear, including delirium, schizophrenia spectrum disorders, bipolar disorder, Parkinson, Huntington, and Alzheimer diseases. Beginning with what we know about the emergence of delusions in these illnesses, we advance a hypothesis of cholinergic disturbance in the dorsal striatum where nicotinic receptors are operative. Striosomes are proposed to play a central role in the formation of delusions. This hypothesis is consistent with our current knowledge about the mechanism of action of cholinergic drugs and with our abstract models of basic cognitive mechanisms at the molecular and circuit levels. We conclude by pointing out the need for further research both at the clinical and translational levels.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.